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Abstract
Patients with long-term type 1 and type 2 diabetes 
mellitus (DM) can develop skeletal complications 
or “diabetic osteopathy”. These include osteopenia, 
osteoporosis and an increased incidence of low-stress 
fractures. In this context, it is important to evaluate 
whether current anti-diabetic treatments can secondarily 
affect bone metabolism. Adenosine monophosphate-
activated protein kinase (AMPK) modulates multiple 
metabolic pathways and acts as a sensor of the cellular 
energy status; recent evidence suggests a critical role 
for AMPK in bone homeostasis. In addition, AMPK 
activation is believed to mediate most clinical effects of 
the insulin-sensitizer metformin. Over the past decade, 
several research groups have investigated the effects 
of metformin on bone, providing a considerable body of 
pre-clinical (in vitro , ex vivo and in vivo) as well as clinical 
evidence for an anabolic action of metformin on bone. 
However, two caveats should be kept in mind when 
considering metformin treatment for a patient with type 
2 DM at risk for diabetic osteopathy. In the first place, 
metformin should probably not be considered an anti-
osteoporotic drug; it is an insulin sensitizer with proven 
macrovascular benefits that can secondarily improve 
bone metabolism in the context of DM. Secondly, we are 
still awaiting the results of randomized placebo-controlled 
studies in humans that evaluate the effects of metformin 
on bone metabolism as a primary endpoint.
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Core tip: Patients with long-term type 1 and type 2 
diabetes mellitus (DM) can develop skeletal compli-
cations. These include osteopenia, osteoporosis and 
increased incidence of low-stress fractures. In this 
context, it is important to evaluate whether current 
anti-diabetic treatments can secondarily affect bone 
metabolism. Over the past decade, several research 
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groups have investigated the effects of metformin on 
bone, providing a considerable body of pre-clinical (in 
vitro , ex vivo  and in vivo) as well as clinical evidence for 
an anabolic action of metformin on bone. This could be 
particularly relevant when considering treatment options 
for DM in the context of diabetic osteopathy.
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INTRODUCTION
Diabetes mellitus (DM) is a highly prevalent global 
disease associated with long-term microvascular and 
macrovascular complications. Over the past 30 years, 
an increasing body of experimental and clinical evidence 
has reported the association of type 1 and type 2 DM 
with osteopenia, osteoporosis and an increased incidence 
of low-stress fractures, in what has been called diabetic 
osteopathy[1]. Many adult patients with type 1 DM 
show mild osteopenia, with a decrease in bone mineral 
density (BMD) of around 10%[2] that would be expected 
to double the risk of non-vertebral fragility fractures[3]. 
However, the incidence of low-stress fractures in type 
1 DM is 7-12 times that of age-matched non-diabetic 
individuals[4,5]. On the other hand, patients with type 2 
DM tend to have normal or even moderately elevated 
BMD. Although this would be expected to reduce 
their incidence of osteoporotic fractures, they actually 
show a 2-fold increase in hip, extremity and vertebral 
fractures[3-7]. Taken together, these clinical observations 
are considered to be evidence for a significant decrease 
in bone quality of patients with both types of DM[8] that 
would explain their increase in low-stress fractures. 
Several mechanisms have been proposed to 
explain diabetic osteopathy, such as disturbed glucose 
metabolism, tissue (bone) and systemic low-grade 
inflammation, changes in the secretory pattern of 
growth factors and/or cytokines, increased oxidative 
stress and excess accumulation of advanced glycation 
end products (AGEs). In particular, excess accumulation 
of AGEs in bone extracellular matrix (ECM) occurs as 
a function of aging and duration of Diabetes, and has 
been found to impair the mechanical properties of 
bone[9]. Poorly compensated DM elevates circulating 
reactive oxygen species (ROS), glucose and/or carbonyl 
stress, which can induce excess AGEs formation on 
bone ECM, reducing bone strength and post-yield 
properties. Additionally, collagen-AGEs interact with the 
receptor for AGEs (RAGE) expressed by osteoblasts 
and osteoclasts, inhibiting their functionality and 
decreasing bone turnover. This induces an even greater 
accumulation of AGEs in bone that contributes to 
diabetic osteopathy, and can increase fracture risk[1]. 
Treatment of patients with DM can include either 
an absolute requirement for exogenous insulin (type 
1 DM), or relative requirement of glucose-lowering 
medication such as insulin and/or oral drugs (type 2 
DM). Oral glucose-lowering agents fall into different 
classes that include (but are not limited to) insulin 
secretagogues, insulin sensitizers, incretin-based treat-
ments and inhibitors of renal proximal tubule glucose 
reabsorption. Each class operates through distinct 
biological pathways and has certain advantages as 
well as disadvantages. Recently, several commonly 
prescribed oral medications for type 2 DM have been 
found to secondarily affect bone metabolism, in some 
cases modifying the incidence of fragility fractures[10]. 
Depending on their specific skeletal effects these drugs 
could either help to prevent diabetic osteopathy, or 
contribute to worsen this complication of DM. 
Members of the thiazolidinediones (TZD) family 
of insulin-sensitizers such as rosiglitazone have been 
shown to be detrimental for bone health. In rodents, 
TZD increase the adipocytic commitment of mesen-
chymal stem cells (MSC) while decreasing their osteo-
genic potential, via a decrease in the Runx2/PPARg ratio. 
This increases bone marrow adiposity and promotes 
bone loss[11]. In the ADOPT clinical trial[12], results 
showed a higher risk of fracture in diabetic women, but 
not men, on rosiglitazone monotherapy.
Post-prandial incretin secretion is believed to 
play a physiological role linking nutrient ingestion to 
suppression of bone resorption and stimulation of bone 
formation. Thus, incretin-based treatments would be 
expected to show anabolic effects on bone, as has 
been suggested in a recent meta-analysis[13]. However, 
this may not be so in certain cases such as the DPP4 
inhibitor saxagliptin, which has been found to impair 
MSC osteogenic potential and bone micro-architecture 
in rodent models[14]. 
Inhibitors of the sodium glucose cotransporter 2 
such as dapagliflozin and canagliflozin, that decrease 
plasma glucose and body weight by impairing proximal 
tubule glucose reabsorption, have recently been asso-
ciated with alterations in mineral metabolism and with 
an increase in bone fractures. This undesirable effect 
is probably due to the fact that these drugs can induce 
hyperphosphataemia and an increase in fibroblast 
growth factor-23 and para-thyroid hormone levels[15].
Metformin is an insulin-sensitizing biguanide that 
was developed several decades ago; however, it is still 
the most widely used oral anti-diabetic medication, 
particularly since the United Kingdom Prospective 
Diabetes Study demonstrated its efficacy for reducing 
macrovascular complications in obese type 2 DM 
patients[16]. Although the exact mechanism of action for 
metformin is still incompletely understood, in various 
tissues and organs it improves glucose metabolism via 
activation of the ubiquitously expressed AMP-activated 
protein kinase (AMPK)[17,18]. AMPK subunit expression 
and activation is tissue-specific, with the a1 subunit 
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phosphorylation. On the contrary, AMPK activation 
increases mitochondrial biogenesis[26]. AMPK can also 
inhibit the proliferation of muscle stem cells, and induce 
the differentiation of endothelial cell progenitors[21]. 
ROLE OF AMPK IN CELL METABOLISM
AMPK functions as an intracellular sensor regulating 
energy balance in different cell types, and thus can 
regulate diverse metabolic pathways (Table 1).
In the liver, AMPK acts as a “metabolic master 
switch”[27]; its activation inhibits energy-consuming 
pathways and stimulates ATP-producing catabolic 
pathways. For instance, after AMPK activation in a 
fasting state, fatty acid synthesis is inhibited while 
mitochondrial oxidative phosphorylation is stimulated. 
These effects occur by a reduction in malonyl-CoA 
content that is mediated by inhibition of Acetyl-CoA 
carboxylase. In addition, malonyl CoA decarboxylase is 
activated, thus further increasing fatty acid oxidation. 
Activation of AMPK also suppresses glucose production 
(gluconeogenesis), as has been demonstrated in 
metformin-treated primary hepatocyte cultures[17]. 
This has been confirmed in mice with a liver-selec-
tive deletion of the AMPKa 2 gene, which exhibit 
hyperglycaemia and glucose intolerance in the fasting 
state[27].
In skeletal muscle, AMPK regulates energy expen-
diture during exercise in order to optimize and enhance 
energy production. It participates in the transition 
from more glycolytic fibres to more oxidative fibres, 
following exercise training[28]. A role for AMPK in the 
myocytic uptake and oxidation of fatty acids has 
also been postulated. In addition, during exercise an 
increase in ATP turnover is accompanied by enhanced 
glucose uptake, in turn associated with an increase 
in myocyte plasma membrane GLUT4 expression[21]. 
Thus, use of metformin in patients with type 2 DM 
will increase their AMPK-induced glucose uptake and 
disposal. AMPK activation has also been postulated to 
induce skeletal muscle regeneration, by regulating its 
post-injury inflammatory response[29]. Postnatal skeletal 
muscle regeneration involves stem cell reprogramming 
that induces their proliferation, differentiation and/or 
self-renovation, and activation of the AMPK pathway 
is believed to regulate these processes[21]. Due to the 
regulatory effects of AMPK on integrated metabolism, 
activation of AMPK is considered a therapeutic target 
for hyperglycaemic states. For instance metformin, an 
anti-diabetic drug that is widely used for treatment of 
patients with type 2 DM, suppresses hepatic glucose 
production and decreases plasma glucose levels via 
activation of AMPK pathways.
The precise effects of AMPK on bone metabolism 
are incompletely known; however, recent evidence 
supports an active role for this kinase in bone physio-
logy[30]. Several reports have demonstrated that AMPK 
modulates bone cell differentiation and function. In 
AMPKa-deleted animals, a reduction was found in 
accounting for most of bone AMPK[19]. Over the last 10 
years, pre-clinical and clinical evidence has accumulated 
pointing to an anabolic effect of metformin on bone, in 
part due to AMPK activation.
AMPK-A KEY ENERGY SENSOR
AMPK is a Ser/Thr protein kinase that modulates 
multiple metabolic pathways and acts as a sensor of 
the cellular energy status[20]. AMPK is a heterotrimer 
of three subunits. The a subunit holds the catalytic 
domain with a Ser/Thr kinase domain (KD). It contains 
a Thr172 residue, critical for the kinase activity. AMPK-a 
also contains a regulatory domain, which interacts with 
the KD of the unphosphorylated inactive form. The b 
subunit contains a carbohydrate-binding module and 
acts as a scaffold for the assembly of a and g subunits. 
It also defines the subcellular localization of AMPK as 
well as its substrate specificity. The g subunit contains 
four cystathionine-b-synthase (CBS) domains, which 
bind adenine nucleotides. Expression of all three 
subunits is required for AMPK activity. The mechanism 
of activation first requires the reversible phosphorylation 
of the a subunit; then after AMP binding to the CBS 
domain of g subunit, an allosteric stimulatory effect 
occurs. Several upstream kinases (AMPKK) are involved 
in the phosphorylation of AMPK, such as liver kinase B1 
(LKB1) and Ca2+/calmodulin-dependent protein kinase 
kinase beta (CaMKKb). Activation of AMPK can occur 
by two mechanisms: One is mediated by an increase 
of AMP/ATP ratio (for instance during exercise), so 
this mechanism coordinates anabolic and catabolic 
pathways to equilibrate nutrient supply with energy 
expenditure[21]. Several compounds can activate AMPK 
by this mechanism: 5-Aminoimidazole-4-carboxamide 
ribonucleotide (AICAR), H2O2, MAPK inhibitors, TZD, 
leptin, adiponectin and a-lipoic acid[22]. In the second 
mechanism, AMPK activation can be independent of 
AMP/ATP ratio and involves alternative AMPK regulation. 
Agents such as peroxynitrite, metformin, estradiol, low 
glucose levels and several membrane receptor agonists 
can induce AMPK activation by this way.
It has recently been demonstrated that AMPK 
can participate in the control of whole-body energy 
homeostasis by integrating signals from diverse 
cellular environments[23]. AMPK participates in several 
physiological events, such as survival, growth and 
development. This kinase could also be implicated 
in pathological conditions such as type 2 DM, insulin 
resistance, cardiovascular disease and cancer. For 
instance, AMPK can control epigenetic processes in 
certain cells to avoid reproductive defects in their 
subsequent generations[24]; or it can suppress proinflam-
matory-signalling pathways in adipocytes[25]. It has 
recently been reported that in patients with insulin 
resistance, AMPK is depressed in adipose tissue; 
an effect that is associated with oxidative stress, 
increased expression of inflammatory cytokines and 
decreased expression of genes regulating oxidative 
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trabecular bone mass[31]. Single a1 or a2 knockout (KO) 
mice are viable, but the double KO is embryonically 
lethal[27]. In addition, histomorphometric analysis 
revealed that AMPKa1 KO mice show an elevated rate 
of bone remodelling in vivo, associated with increased 
osteoclastogenesis in vitro. 
In vitro experiments have demonstrated that 
AMPK activation enhances osteogenesis[30,32] while 
compound C (an AMPK inhibitor) reduces osteoblastic 
mineralization[30]. In other experiments AICAR (an 
activator of AMPK) was found to stimulate alkaline 
phosphatase activity (ALP) and mineral nodule 
formation by rat calvaria-derived cells, while compound 
C suppressed these effects[33]. A decrease in AMPK 
activity has been reported during osteoblastic 
differentiation; this could be associated with the high-
energy requirements of maturing osteoprogenitor 
cells[34]. Although studies of AMPK action on bone 
resorption have led to conflicting results, it appears 
that AMPK is a negative regulator for RANKL and can 
thus decrease osteoclast-mediated bone resorption[35]. 
The AMPK pathway may also be involved in regulating 
the fate of bone marrow stromal cells (MSC) toward 
the osteoblastic or adipocytic lineage by reciprocally 
regulating the expression of Runx2 and PPARg[30]. AMPK 
has been shown on one hand to induce phosphorylation 
of b-catenin, suppress PPARg expression and thus 
reduce adipogenesis[36]; while on the other hand it 
increases Runx2 expression and thus osteoblastic 
differentiation of MSC[37]. This evidence suggests a 
critical role for AMPK in bone homeostasis. 
MOLECULAR MECHANISMS OF 
METFORMIN ACTION
Metformin has been widely used in the United States 
since 1995 as an oral anti-diabetic treatment for type 2 
DM[22]. Even though its precise mechanism of action is 
not completely known, metformin is known to activate 
AMPK[17]; however, AMPK-independent pathways have 
also been postulated[38].
Metformin can be incorporated into cells by a 
facilitated mechanism that is mediated by different 
isoforms of the organic cation transporter. Metformin 
induces mild and specific inhibition of the mitochondrial 
respiratory chain complex in hepatocytes and other 
tissues[39]; it can also inhibit the mitochondrial 
production of ROS. Inhibition of mitochondrial activity 
induces a decrease in the cell energy status, which in 
turn triggers depletion of ATP and a diminished ATP/
AMP ratio. This effect then induces phosphorylation and 
activation of AMPK via LKB1. Metformin also induces 
an acute inhibition of gluconeogenesis: this can be 
explained by the decrease in ATP/AMP ratio, which 
inhibits key enzymes of the gluconeogenic pathway 
such as fructose-1,6-bisphosphatase. New evidence 
suggests that this metformin-induced inhibition of 
glucose production could also be mediated by a down-
regulation of gluconeogenic genes via a transcription-
independent process. It has been suggested that 
reduction in energy status, but not AMPK activation, 
is critical for metformin inhibition of hepatic glucose 
production[38].
In addition to its effects in the liver, metformin 
can also affect other organs via multiple molecular 
mechanisms. One important action of metformin is 
its reduction of endothelial activation and of athero-
genesis[16]. Metformin decreases intracellular ROS 
production in endothelial cells by inhibiting both NADPH 
oxidation and the respiratory chain complex[40], and this 
effect appears to be independent of AMPK activation.
METFORMIN MEETS BONE
Over the past decade, several research groups have 
investigated the effects of metformin on bone. The 
results of these studies are discussed in detail below. 
They have provided a considerable body of pre-clinical (in 
vitro, ex vivo and in vivo) as well as clinical evidence for 
an anabolic action of metformin on bone, which could 
be particularly relevant when considering treatment 
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  Organ Effect Mechanism of action Ref.
  Liver Inhibition of anabolic pathways Inhibition of fatty acid synthesis [27]
Inhibition of gluconeogenesis
Stimulation of ATP synthesis Stimulation of Mitochondrial oxidative phosphorylation [27]
  Skeletal muscle Regulation of energy expenditure 
during exercise
Favours the transition from glycolitic to oxidative skeletal muscle fibers [28]
Regulation of myocitic uptake and oxidation of fatty acids [21]
Enhanced glucose uptake via an increase in GLUT4 expression [21]
Increase in skeletal muscle 
regeneration
Regulation of post-injury inflammatory response [29]
Stem cell reprogramming: Induction of proliferation, differentiation and self-renewal [21]
  Bone Increase in osteoblastogenesis Increases MSC differentiation towards the osteoblastic lineage favouring Runx2 
expression 
[30,37]
Decreases PPARg expression diminishing MSC differentiation towards the adipocytic 
phenotype
[36,37]
Decrease in osteoclastogenesis Negative regulation of RANKL expression by osteoblasts [35]
Table 1  Role of AMP-activated protein kinase activation on cell metabolism in different organs
MSC: Mesenchymal stem cells; ATP: Adenosine triphosphate; GLUT4: Glucose transporter type 4; RANKL: Receptor activator for nuclear factor κB ligand.
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options for DM in the context of diabetic osteopathy.
In vitro effects of metformin on bone cells
Metformin has been found to modulate the physiology 
of osteoblasts (Figure 1) and osteoclasts, as well as 
influencing the phenotypic progression of bone MSC. 
Cortizo et al[41] were the first to describe an in vitro 
effect of metformin on bone-derived cells, showing that 
it dose-dependently increased osteoblastic proliferation, 
differentiation and mineralization. This effect was 
mediated by activation of extracellular-regulated 
kinases and by induction of NO synthases. Several 
researchers have corroborated these results[19,42-44], 
additionally showing that the osteogenic in vitro action 
of metformin on osteoblasts is dependent on activation 
of the AMPK signalling pathway and subsequent bone 
morphogenetic protein-2 production. In an interesting 
mechanistic study, Jang et al[45] found that metformin 
increased the osteoblastic transcription of small hetero-
dimer partner (SHP) and osteocalcin genes, an effect 
that was inhibited either by a dominant negative form 
of AMPK or by compound C. They also found that 
metformin-induced SHP gene expression was mediated 
by upstream stimulatory factor-1 (USF-1), that AMPK 
activation increased the expression of Runx2 and that 
SHP interacts physically and forms a complex with 
Runx2 on the osteocalcin gene promoter in osteoblastic 
cells. Thus, metformin appears to enhance osteoblast 
differentiation through the transactivation of Runx2 
via the AMPK/USF-1/SHP regulatory cascade[45]. In 
another study, Mai et al[46] found that metformin dose-
dependently stimulated osteoprotegerin (OPG) and 
reduced receptor activator of nuclear factor-κB ligand 
(RANKL) mRNA and protein expression by cultured 
osteoblastic cells, a potentially anti-osteoclastogenic 
effect that they were able to block by inhibition of 
AMPK[46].
Since one of the proposed mechanisms for diabetic 
osteopathy is hyperglycaemia-mediated accumulation 
of AGEs on bone collagen, and AGEs can decrease 
osteoblastic maturation and survival via binding to their 
receptor RAGE, Schurman et al[47] investigated whether 
this process could be modulated in vitro by metformin. 
They found that metformin was able to prevent the 
increase in apoptosis, caspase 3 activity, inhibition 
of ALP and alterations in intracellular oxidative stress 
induced by AGEs in osteoblastic cells, via a metformin-
dependent down regulation in the osteoblastic expre-
ssion of RAGE[47]. In another study, Zhen et al[33] 
evaluated whether metformin could prevent the anti-
proliferative effect of high-glucose exposure on primary 
osteoblasts in culture. They found that incubation 
with metformin decreased the high-glucose-induced 
intracellular ROS production and apoptosis, and that it 
additionally induced an osteogenic effect on osteoblasts 
that was mediated by an increase in Runx2 and IGF-1 
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Figure 1  Metformin actions via osteoblasts are pro-osteogenic and anti-resorptive. Metformin is incorporated into osteoblasts, where it inhibits intracellular 
ROS production and induces AMPK phosphorylation/activation. This increases eNOS activity and NO production, promoting osteoblast proliferation. In addition, 
activated AMPK up regulates osteoblastic differentiation and mineralization via expression of Runx2 and SHP, while decreasing osteoclastic recruitment and bone-
resorbing activity through a reduction in osteoblastic RANKL/OPG ratio. ROS: Reactive oxygen species; AMPK: AMP-activated protein kinase; OPG: Osteoprotegerin; 
RANKL: Reduced receptor activator of nuclear factor-κB ligand; SHP: Small heterodimer partner; RUNX2: Runt-related transcription factor 2; AMP: Adenosine 
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gene expression[33]. These results have been recently 
confirmed by other investigators[48].
Three different studies have investigated the in 
vitro effects of metformin on stromal cells isolated 
from bone marrow (MSC). In the first report, Gao 
et al[49] found that metformin increased Runx2 and 
decreased PPARg expression, and consequently 
stimulated ALP and mineralization while inhibiting the 
intracellular accumulation of lipid droplets. These results 
suggest that metformin could influence the reciprocal 
relationship between osteoblastic and adipogenic 
differentiation of MSC, tipping the balance towards 
osteogenesis. Molinuevo et al[37] further demonstrated 
that metformin could induce an in vitro dose-dependent 
increase in MSC osteogenic potential (ALP, type 1 
collagen secretion and mineralization). They also found 
that metformin dose-dependently prevents rosiglitazone-
induced intracellular lipid accumulation by MSC[37]. In 
another study, Sedlinsky et al[50] demonstrated that the 
in vitro osteogenic effect of metformin on MSC is AMPK-
dependent, and that it can be completely blocked by 
the AMPK inhibitor compound C.
Metformin has also been found to modulate in 
vitro osteoclast recruitment, differentiation and bone-
resorbing activity in some[35,46,51] but not all[52] published 
reports. OPG and RANKL are predominantly secreted 
by osteoblasts and play critical roles in osteoclast 
physiology. As stated above, in vitro experiments have 
shown that metformin increases OPG and reduces 
RANKL mRNA and protein expression by osteoblasts, 
which is potentially anti-osteoclastogenic. Additionally, 
when a macrophage cell line was incubated with the 
supernatant of osteoblasts treated with metformin, 
this reduced the formation of tartrate resistant acid 
phosphatase (TRAP)-positive multi-nucleated osteo-
clasts[46]. In another interesting in vitro study, AMPK was 
found to be expressed by bone marrow pre-osteoclasts 
and as such is a regulatory target for osteoclast 
differentiation and resorptive activity. Pharmacological 
inhibition of pre-osteoclastic AMPK with compound 
C increased the RANKL-induced formation of TRAP-
positive multinucleated cells and their resorptive activity 
on dentine discs, via downstream activation of p38, JNK, 
NF-κB, Akt, CREB, c-Fos, and NFATc1. On the contrary, 
metformin dose-dependently suppressed formation 
of TRAP-positive multinucleated cells and dentine 
resorption[35]. In unpublished results using indirect 
immunofluorescence, we have found a metformin-
induced increase and sub-cellular redistribution in 
phosphorylated (activated) AMPK of multinucleated 
osteoclasts obtained from osteoblast-macrophage co-
cultures (Figure 2), which could be mediating the effects 
of metformin in this cell type.
All in all, these in vitro results point to a global bone-
anabolic effect of metformin: Tipping the phenotypic 
balance of bone MSC towards osteoblastogenesis, 
increasing the bone-forming capacity of osteoblasts, 
and decreasing the recruitment and bone-resorbing 
activity of osteoclasts (Figure 3). These findings are 
further supported by in vivo and ex vivo (pre-clinical) 
as well as clinical evidence, pointing to an osteogenic 
action of metformin in the context of DM. 
In vivo and ex vivo effects of metformin on bone 
metabolism: Animal models
Most studies using animal models (but not all) have 
shown beneficial actions of metformin on bone meta-
bolism and on bone lesion repair (Figure 4). 
Molinuevo et al[37] demonstrated an ex vivo osteogenic 
effect of metformin: i.e., that bone MSC obtained from 
rats after a 2-wk treatment with oral metformin, exhibit 
increased osteogenic potential (Runx2 expression, 
ALP activity, type 1 collagen production, osteocalcin 
synthesis, and mineral nodule deposition) vs MSC 
obtained from non-treated animals. In addition, these 
metformin-induced effects were found to be secondary 
to AMPK activation. In this study, metformin treatment 
also stimulated the repair of a minimal parietal lesion in 
vivo, both in diabetic and non-diabetic rats.
As stated above, rosiglitazone is a TZD that induces 
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Figure 2  Metformin induces an increase and redistribution of activated AMP-activated protein kinase in multinucleated osteoclasts. UMR106 osteoblasts 
and Raw 264.7 macrophages were co-cultured for 7 d, in the absence (A) or presence (B) of 500 mol/L metformin. Cells were  fixed, permeabilized and incubated 
with an anti-phosphorylated AMPK antibody, followed by a FITC-conjugated secondary antibody (green). Nuclei were counterstained with propidium iodide (red). Cells 
were visualized with a Leica TSC SP5 AOBS confocal microscope. Metformin induced an increase in activated AMPK with a punctillate and predominantly cytoplasmic 
distribution. AMPK: AMP-activated protein kinase. 
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deleterious effects on osteoblast differentiation[53] and 
on osteocyte survival[54], diverting MSC differentiation 
toward the adipocyte lineage. In view of the opposite 
effect that has been demonstrated for metformin on 
these cell types, Sedlinsky et al[50] investigated the 
effect of a 2-wk metformin/rosiglitazone combined 
oral treatment of rats on long-bone metaphyseal 
microarchitecture, minimal parietal lesion repair and 
MSC osteogenic potential. Compared to untreated 
controls, rosiglitazone monotherapy decreased femoral 
metaphysis trabecular area, osteoblastic and osteocytic 
density, and TRAP activity associated with epiphyseal 
growth plates. In addition, it greatly diminished 
bone repair. It also decreased the ex vivo osteogenic 
potential of MSC, inducing an increase in PPARg and a 
decrease in Runx2 expression, as well as a decrease in 
phosphorylated (active) AMPK. Metformin/rosiglitazone 
co-treatment prevented all the in vivo (bone repair 
and diaphyseal microarchitecture) and ex vivo anti-
osteogenic effects of rosiglitazone monotherapy, with 
a reversion back to control levels of PPARg, Runx2 and 
AMPK phosphorylation in MSC[50].
In another study, the skeletal (femoral) effects of 
rosiglitazone were compared to those of metformin 
in insulin-resistant female C57BL6J ob/ob mice. The 
metformin-treated group showed higher BMD, higher 
trabecular bone volume/total bone volume, higher 
osteoid width and mineral apposition, lower trabecular 
spacing and lower bone marrow adiposity, when 
compared with the rosiglitazone-treated group[55].
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Figure 4  Actions of metformin on bone metabolism - animal studies. Orally administered metformin promotes the osteogenic potential of bone MSC, increases the 
quality of bone tissue (improving its micro-architecture and mineral density) and facilitates the repair of bone lesions. In addition, metformin may prevent experimental 
diabetic osteopathy as well as ovariectomy-induced bone loss. MSC: Marrow stromal cells; BMD: Bone mineral density; p-AMPK: Phosphorylated AMP-activated kinase.
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Figure 3  Effects of metformin on bone-derived cells. The results of several in vitro studies show that metformin modulates the phenotypic balance of bone marrow 
stromal cells (MSC) away from adipogenesis and towards osteoblastogenesis. In addition, metformin increases in vitro the bone-forming capacity of osteoblasts, 
while decreasing the recruitment and bone-resorbing activity of osteoclasts. ALP: Alkaline phosphatase; TG: Triglycerides; TRAP: Tartrate-resistant acid phosphatase; 
RANK: Receptor activator for nuclear factor κB; RANKL: RANK ligand.
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Gao et al[56] studied the in vivo effect of oral 
metformin on bone mass in ovariectomized rats. They 
found that metformin dose-dependently reverted 
ovariectomy-induced bone loss, showing an improve-
ment in BMD measured by DEXA, and in bone 
microarchitecture measured both by micro CT and by 
bone histology. By real-time PCR of MSC, they found a 
metformin-dependent increase in Runx2 and Lrp5 (co-
receptor for Wnt) expression, both of which are involved 
in osteoblastic proliferation and differentiation[56].
In another report, Jeyabalan et al[57] studied either 
ovariectomized C57BL/6 mice or young Wistar rats 
to evaluate the effect of oral metformin on bone 
metabolism and fracture repair, respectively. In both 
models, metformin did not modify bone microar-
chitecture or cellular activity in vivo as evaluated by 
micro-CT and bone histomorphometry. In addition, 
metformin had no significant effect on the repair of a 
midshaft femoral fracture in Wistar rats[57].
Mai et al[46] further investigated the effects on bone 
of an oral metformin treatment in ovariectomized 
(OVX) adult rats. They found that metformin treatment 
of OVX animals significantly increased total body 
BMD, enhanced bone mineral content and decreased 
trabecular separation; supporting the concept that 
metformin can prevent OVX-induced bone loss. The 
authors also found that metformin reverted the OVX-
associated increase in TRAP-positive osteoclasts of 
proximal tibiae resorption pits. Metformin treatment also 
increased serum OPG, and decreased RANKL expression 
by MSC, in OVX rats. Further in vitro experiments 
showed that these effects were regulated by AMPK and 
by its upstream activator CaMKK.
In a rat model of partially insulin-deficient nicotina-
mide/streptozotocin-induced DM, tibia histomor-
phometry showed a diabetes-induced decrease in 
trabecular bone volume, osteocyte density, growth 
plate height and osteoclast (TRAP positive) activity in 
the primary spongiosa, as well as an increase in bone 
marrow adiposity. MSC from diabetic animals showed 
a decrease in their osteoblastic potential, an increase 
in adipocytic commitment, a reduction in their Runx2/
PPARg ratio and an increased expression of the AGEs 
receptor RAGE. A 2-wk oral treatment with metformin 
prevented all these Diabetes-induced alterations in bone 
micro-architecture and MSC osteogenic potential, and 
also induced a down-regulation of RAGE expression by 
MSC[58].
Clinical evidences of metformin effects on bone
There are few published clinical studies reporting the 
skeletal effects of metformin. In addition, randomized 
placebo-controlled studies in humans that evaluate the 
effects of metformin on bone metabolism as a primary 
end point are so far unavailable. The results of published 
clinical reports are summarized in Table 2. 
Several epidemiological studies have reported the 
effects of diabetes and antidiabetic agents on bone 
fracture risk. In 2005, Vestergaard et al[59] published 
a Danish population-based study evaluating risk of 
fractures and its relationship with T1DM and T2DM 
and anti-diabetic agents. They found that both T1DM 
and T2DM patients had a significant increase in bone 
fracture risk, and that the use of metformin was 
associated with a significantly decreased risk for fracture 
at any site.
Melton et al[6] conducted another population-based 
study in Rochester, United States, to evaluate fracture 
risk factors in T2DM patients. They found that patients 
had an increased risk of hip fracture after 10 years of 
DM, and that use of biguanides such as metformin was 
protective even after adjusting for other risk factors (HR, 
0.7; 95%CI: 0.6-0.96).
Monami et al[60] conducted a case-control study, 
nested within a retrospective cohort, comparing 83 
case subjects with a history of bone fractures and 249 
control subjects, in all cases exposed to insulin, insulin 
secretagogues or metformin treatment for the past 
10 years, in order to assess the risk for bone fractures 
associated with exposure to insulin or different oral 
hypoglycaemic agents. This study was unable to 
demonstrate a reduction in bone fractures associated 
with metformin treatment, but showed an increased rate 
of fractures in patients on insulin treatment, probably 
related to worse diabetes control or to hypoglycaemic 
episodes. Nevertheless, the authors acknowledged that 
the lack of a statistically significant fracture reduction 
associated with metformin treatment was probably 
related to an insufficient sample size.
The ADOPT study (A Diabetes Outcome Progression 
Trial), that compared the glycaemic effects of 
rosiglitazone, metformin and glyburide, showed that 
among the adverse effects of rosiglitazone was an 
increased risk of fracture in women. At the same 
time they showed that metformin had a lower risk of 
fracture, both in women and men, for every skeletal site 
assessed[12]. In an add-on report to the ADOPT study, 
C-telopeptide levels (CTX, a bone resorption marker) 
were found to be reduced by metformin treatment and 
increased in rosiglitazone-treated patients, suggesting 
that changes in bone resorption may be partly 
responsible for the differences in fracture risk observed 
for both treatments[61].
A randomized, parallel group, double-blind, multicentre 
study comparing the efficacy and safety of rosiglitazone/
metformin co-treatment (RSG/MET) vs metformin 
monotherapy (MET) was conducted in order to assess 
glycaemic control and BMD after 80 wk of treatment 
in drug-naïve T2DM patients. Although the RSG/MET 
combination was superior to MET in achieving significant 
reductions in glycated haemoglobin and fasting plasma 
glucose, RSG/MET was associated with a significantly 
lower BMD in comparison with MET at week 80 in the 
hip and lumbar spine[62].
In another study, Hegazy[63] evaluated the possible 
anti-osteoporotic effect of metformin vs sitagliptin in 40 
post-menopausal diabetic women. They were randomly 
divided into two groups, one receiving 500 mg 
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metformin twice a day, and the other 100 mg sitagliptin 
once a day, for 12 wk. In the metformin-treated group, 
serum ALP and urinary D-piridinoline (DPD) were not 
significantly different from baseline; conversely in the 
sitagliptin group, serum ALP and urinary DPD decreased 
significantly after 12 wk, although BMD was unchanged 
in both groups.
The effects of pioglitazone and metformin on 
circulating sclerostin (an osteocyte-derived osteoblast 
proliferation inhibitor), and biochemical markers of 
bone turnover were studied in 71 men with T2DM. 
This group as a whole showed higher serum sclerostin 
levels than healthy controls. Sclerostin levels were 
further increased in the sub-set of patients that were 
treated with pioglitazone, who also showed an increase 
in serum CTX. On the contrary, metformin-treated 
patients vs healthy controls showed significantly 
lower sclerostin levels and unchanged CTX levels[64]. 
Although sclerostin is a well-established inhibitor of 
bone formation, recent evidence indicates that it can 
also promote osteoclastogenesis by stimulating RANKL 
produced by osteocytes[65], suggesting that pioglitazone 
could increase bone resorption while decreasing 
bone formation, and the opposite would occur with 
metformin.
Finally, metformin was tested for bone-defect healing 
purposes in a clinical study, adding this biguanide to 
platelet-rich fibrin in order to treat intrabony defects 
in patients with chronic periodontitis. The study was 
designed to evaluate the efficacy of platelet-rich fibrin, 
1% metformin gel, or platelet-rich fibrin plus 1% 
metformin gel, in all cases with open flap debridement, 
for treatment of intrabony defects in 120 patients with 
chronic periodontitis. The group treated with platelet-
rich fibrin plus 1% metformin gel showed the greatest 
improvements in clinical parameters, with an increase 
in percentage radiographic defect depth reduction when 
compared to metformin alone, platelet-rich fibrin alone 
or open flap debridement alone[66].
CONCLUSION AND PERSPECTIVES
Patients with long-term T1 DM and T2 DM can develop 
skeletal complications or “diabetic osteopathy”. These 
include osteopenia, osteoporosis and an increased 
incidence of low-stress fractures. In this context, it is 
important to evaluate whether current anti-diabetic 
treatments can secondarily affect bone metabolism. 
Over the past 10 years, many investigators have 
studied the effects of metformin on bone, providing a 
considerable body of pre-clinical (in vitro, ex vivo and in 
vivo) as well as clinical evidence for an anabolic action 
of metformin on bone. However three reports (one in 
vitro, one in vivo, one clinical) have been unable to link 
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  Study design Study population n Outcome Ref. 
  Case control study All subjects with bone fracture in Denmark 
(year 2000), vs 3-fold controls
124655 fracture patients
373962 control 
Fracture risk = 0.81 (95%CI: 0.70-0.93)1
(for metformin)
[59]
  Cohort Study Rochester residents first meeting Diabetes 
glycaemic criteria (1970-1994)
1964 diabetic patients Fracture risk = 0.7 (95%CI: 0.6-0.96)2
(for metformin)
[6]
  Case control study A study nested within a cohort of 1945 
diabetic Tuscany outpatients (1998-2004) 
83 fracture patients 
249 control
Fracture risk = 0.60 (95%CI: 0.34-1.08)3
 (for metformin)
[60]
  Double-blind, 
  randomized, controlled 
  clinical trial
Recently diagnosed, drug-naïve patients 
with type 2 diabetes, treated for a median 
of 4 yr with rosiglitazone, metformin, or 
glyburide
Rosiglitazone: 
n = 1456; Metformin: 







  Double-blind, 
  randomized, controlled 
  clinical trial
Recently diagnosed, drug-naïve patients 
with type 2 diabetes, treated for a median 
of 4 yr with RSG, MET, or GLY
Paired baseline and 12-mo 
stored serum samples 
from 1605 patients 
In women, CTX increased by 6.1% with RSG, 
decreased by 1.3% with MET (P = 0.03)
In men, CTX was unchanged on RSG (-1.0%) 
and fell with MET -12.7% (P = 0.001)
[61]
  Randomized, parallel 
  group, double-blind, 
  multicentre study
Drug naïve, male and female patients who 
had an established clinical diagnosis of type 
2 diabetes mellitus
688 patients equally 
randomized to RSG/MET 
or MET
BMD at week 80:
Lumbar = (-2.2) (95%CI: -3.5, -0.9)
Total hip = (-1.5) 
(95%CI: -2.3, -0.7)5
[62]
  Prospective randomized 
  study with active
  comparator study
Forty postmenopausal diabetic women 
recruited from Tanta University Hospitals
20 patients on metformin 
and 20 on sitagliptin, for 
12 wk
BMD was unchanged in both groups at 
week 12
Bone turnover markers remained unchanged 
from baseline in MET
[63]
  Prospective randomized 
  double-blind, 
  double-dummy with 
  active comparator
Men with uncomplicated type 2 diabetes 
mellitus, aged 45-65 yr
71 men were randomized 
to PIO once daily or MET 
twice daily
Sclerostin levels at week 24 increased by 
11% in PIO-treated patients and decreased 
by 1.8% in MET-treated patients (P = 0.018)
[64]
Table 2  Clinical evidences of metformin effects on bone
1Relative risk of any fracture interpreted as OR with 95%CI for several variables in the population of Denmark (National Health Registry, year 2000); 
2Multivariate HR for the development of any new fracture among 1964 Rochester, MN, United States residents after recognition of diabetes mellitus in 
1970-1994; 3Exposure for at least 36 mo to hypoglycemic treatments in case subjects and matched control subjects, interpreted as OR with 95%CI; 4P < 0.01 
for comparison of fracture risk in women with rosiglitazone (unadjusted, contingency χ 2 test); 5Percentage of change in BMD at week 80, comparing RSG/
MET vs MET. RSG: Rosiglitazone; MET: Metformi; GLY: Glyburide; PIO: Pioglitazone; BMD: Bone mineral density; OR: Odds ratio; HR: Hazard ratios.
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metformin treatment with bone anabolic processes, 
underscoring the differences that exist between 
experimental models in pre-clinical studies, and the low 
statistical potency inherent in clinical reports that include 
a relatively small number of patients. In this sense, 
two caveats should be kept in mind when considering 
metformin treatment for a patient with T2DM at risk for 
diabetic osteopathy. In the first place, metformin should 
probably not be considered an anti-osteoporotic drug; 
it is an insulin sensitizer with proven macrovascular 
benefits that can secondarily improve bone metabolism 
in the context of DM. Secondly, we are still awaiting 
the results of randomized placebo-controlled studies in 
humans that evaluate the effects of metformin on bone 
metabolism as a primary endpoint.
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